Company Profile

Kaps Biotech Inc
Profile last edited on: 10/30/2019      CAGE: 7SML9      UEI: X5H8TALYK5R3

Business Identifier: Technology to detect prostate cancer
Year Founded
----
First Award
2018
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5800 Sheridan Drive
Williamsville, NY 14221
   (734) 717-9365
   N/A
   www.kapsbio.com
Location: Single
Congr. District: 26
County: Erie

Public Profile

With the objective of improving the early detection, treatment and survival of cancer patients, KAPS Biotech is focused on the development of new cancer biomarkers. Involving practioners longtime focused on improving cancer outcomes, principals of the firm are structured around bringing the full in-use condition a unique panel of biomarker(s) for the early detection of PCa that can inform treatment decision making and improve monitoring men with PCa. The firm's previous work has shown that the known drawbacks of currently available PSA test can be overcome by their panel of biomarkers that are able to differentiate benign prostate and PCa with greater specificity and identify men who have high risk (aggressive) PCa.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $1,724,998
Project Title: KAPS Biotech: a Novel Biomarker to Improve Prostate Cancer Diagnosis

Key People / Management

  Kailash C Chadha

  Willie Underwood

  Ruben Williams